Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients.

Gilli S, Novak U, Taleghani BM, Baerlocher GM, Leibundgut K, Banz Y, Zander T, Betticher D, Egger T, Rauch D, Pabst T.

Ann Hematol. 2017 Mar;96(3):421-429. doi: 10.1007/s00277-016-2900-y. Epub 2016 Dec 24.

PMID:
28011985
2.

A retrospective, matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen: results from a single center experience.

Saleh K, Danu A, Koscielny S, Legoupil C, Pilorge S, Castilla-Llorente C, Ghez D, Lazarovici J, Michot JM, Khalife-Saleh N, Lapierre V, Alenxandrova K, Arfi-Rouche J, Bourhis JH, Ribrag V.

Leuk Lymphoma. 2017 Nov 22:1-8. doi: 10.1080/10428194.2017.1403019. [Epub ahead of print]

PMID:
29164977
3.

Comparable safety profile of BeEAM (bendamustine, etoposide, cytarabine, melphalan) and BEAM (carmustine, etoposide, cytarabine, melphalan) as conditioning before autologous haematopoietic cell transplantation.

Frankiewicz A, Saduś-Wojciechowska M, Najda J, Czerw T, Mendrek W, Sobczyk-Kruszelnicka M, Soska K, Ociepa M, Hołowiecki J, Giebel S.

Contemp Oncol (Pozn). 2018;22(2):113-117. doi: 10.5114/wo.2018.77046. Epub 2018 Jun 30.

4.

A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.

Martino M, Tripepi G, Messina G, Vincelli ID, Console G, Recchia AG, Gentile M, Molica S, Morabito F.

Bone Marrow Transplant. 2016 Sep;51(9):1197-203. doi: 10.1038/bmt.2016.94. Epub 2016 Apr 18.

PMID:
27088375
5.

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.

Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Giardini C, Falcioni S, Cuberli F, Gobbi M, Sarina B, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Isidori A.

Blood. 2011 Sep 22;118(12):3419-25. doi: 10.1182/blood-2011-04-351924. Epub 2011 Aug 3.

6.

Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective.

Reid RM, Baran A, Friedberg JW, Phillips GL 2nd, Liesveld JL, Becker MW, Wedow L, Barr PM, Milner LA.

Cancer Med. 2016 Nov;5(11):3059-3067. doi: 10.1002/cam4.879. Epub 2016 Oct 3.

7.

Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.

William BM, Loberiza FR Jr, Whalen V, Bierman PJ, Bociek RG, Vose JM, Armitage JO.

Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):417-23. doi: 10.1016/j.clml.2013.03.009. Epub 2013 Jun 15.

PMID:
23773453
8.

Z-BeEAM (Ibritumomab tiuxetan, Bendamustine, Etoposide, Cytarabine, Melphalan) before autologous stem cell transplantation is safe and efficient for refractory large B-cell lymphoma.

Tardy MP, Gastaud L, Ojeda-Uribe M, Boscagli A, Caruso S, Skaf R, Gutnecht J, Thyss A, Peyrade F.

Exp Hematol Oncol. 2015 Jul 4;4:18. doi: 10.1186/s40164-015-0013-2. eCollection 2015.

9.

High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma.

Rossi HA, Becker PS, Emmons RV, Westervelt P, Levy W, Liu Q, Clark Y, Ballen K.

Bone Marrow Transplant. 2003 Mar;31(6):441-6.

PMID:
12665838
10.

Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.

William BM, Allen MS, Loberiza FR Jr, Bociek RG, Bierman PJ, Armitage JO, Vose JM.

Biol Blood Marrow Transplant. 2014 Apr;20(4):536-42. doi: 10.1016/j.bbmt.2014.01.004. Epub 2014 Jan 14.

11.

A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.

Mark TM, Reid W, Niesvizky R, Gergis U, Pearse R, Mayer S, Greenberg J, Coleman M, Van Besien K, Shore T.

Biol Blood Marrow Transplant. 2013 May;19(5):831-7. doi: 10.1016/j.bbmt.2013.02.013. Epub 2013 Feb 20.

12.

Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue--a highly effective regimen for patients with refractory or relapsed indolent lymphoma.

Josting A, Reiser M, Wickramanayake PD, Rueffer U, Draube A, Söhngen D, Tesch H, Wolf J, Diehl V, Engert A.

Leuk Lymphoma. 2000 Mar;37(1-2):115-23.

PMID:
10721775
13.

Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma.

Arai S, Letsinger R, Wong RM, Johnston LJ, Laport GG, Lowsky R, Miklos DB, Shizuru JA, Weng WK, Lavori PW, Blume KG, Negrin RS, Horning SJ.

Biol Blood Marrow Transplant. 2010 Aug;16(8):1145-54. doi: 10.1016/j.bbmt.2010.02.022. Epub 2010 Mar 1.

14.

High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.

Durando X, Lemaire JJ, Tortochaux J, Van-Praagh I, Kwiatkowski F, Vincent C, Bailly C, Verrelle P, Irthum B, Chazal J, Bay JO.

Bone Marrow Transplant. 2003 Apr;31(7):559-64.

PMID:
12692621
15.

BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.

Kim JE, Lee DH, Yoo C, Kim S, Kim SW, Lee JS, Park CJ, Huh J, Suh C.

Leuk Res. 2011 Feb;35(2):183-7. doi: 10.1016/j.leukres.2010.07.016. Epub 2010 Aug 3.

PMID:
20684990
16.

Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation.

Cao TM, Negrin RS, Stockerl-Goldstein KE, Johnston LJ, Shizuru JA, Taylor TL, Rizk NW, Wong RM, Blume KG, Hu WW.

Biol Blood Marrow Transplant. 2000;6(4):387-94.

17.

High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.

Noesslinger T, Panny M, Simanek R, Moestl M, Boehm A, Menschel E, Koller E, Keil F.

Eur J Haematol. 2018 Sep;101(3):326-331. doi: 10.1111/ejh.13102. Epub 2018 Aug 3.

PMID:
29799642
18.

BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.

Veeraputhiran M, Jain T, Deol A, Ayash L, Kim S, Dyson G, Bhutani D, Lum LG, Ratanatharathorn V, Uberti JP, Abidi MH.

Clin Lymphoma Myeloma Leuk. 2015 Sep;15(9):531-5. doi: 10.1016/j.clml.2015.05.008. Epub 2015 Jun 6.

PMID:
26166312
19.

Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.

Musso M, Scalone R, Marcacci G, Lanza F, Di Renzo N, Cascavilla N, Di Bartolomeo P, Crescimanno A, Perrone T, Pinto A.

Bone Marrow Transplant. 2010 Jul;45(7):1147-53. doi: 10.1038/bmt.2009.318. Epub 2009 Nov 9.

PMID:
19898504
20.

Supplemental Content

Support Center